|1.||Blum, David: 3 articles (09/2009 - 01/2008)|
|2.||Quessy, Steve: 2 articles (09/2009 - 06/2009)|
|3.||Chessell, Iain P: 2 articles (03/2007 - 03/2005)|
|4.||Brown, Terry: 2 articles (03/2005 - 11/2004)|
|5.||Stevens, Alexander: 2 articles (03/2005 - 11/2004)|
|6.||Naylor, Alan: 2 articles (03/2005 - 11/2004)|
|7.||Bountra, Chas: 2 articles (03/2005 - 11/2004)|
|8.||Bingham, Sharon: 2 articles (03/2005 - 11/2004)|
|9.||Haslam, Claudine: 2 articles (03/2005 - 11/2004)|
|10.||Wiseman, Joanne: 2 articles (03/2005 - 11/2004)|
|1.||Neuralgia (Stump Neuralgia)
03/01/2007 - "These results illustrate that COX-2 may indeed play an important role in the maintenance of neuropathic pain following nerve injury, but that only certain COX-2 inhibitors, such as GW406381, are effective in this paradigm. "
03/01/2005 - "The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization."
03/01/2005 - "The novel finding of effectiveness of GW406381X in these models of neuropathic pain/central sensitization, in addition to activity in inflammatory pain models and together with its central efficacy, suggests dual activity of GW406381X compared with celecoxib and rofecoxib, which may translate into greater efficacy in a broader spectrum of pain states in the clinic."
01/01/2008 - "Study A demonstrated that GW406381 50 mg was superior to placebo on WOMAC pain subscore (mean difference from placebo -6.9 mm; P= .012). "
06/01/2009 - "Both doses of GW406381 produced greater reduction in pain score than placebo, but the treatment difference did not reach statistical significance. "
01/01/2008 - "Overall, clinically meaningful efficacy in pain related to OA of the knee was not demonstrated for GW406381 despite its peripheral and central sites of action."
09/01/2009 - "GW406381 50 and 70 mg demonstrated clinically meaningful analgesia in this acute pain setting, although the onset of analgesia was greater than 1 hour."
04/01/2008 - "The primary end-point was the proportion of subjects with headache relief [reduction in headache severity score from pre-dose 2 (moderate) or 3 (severe) to 0 (no pain) or 1 (mild)] at 2 h post-dose for GW406381 compared with placebo. "
06/01/2009 - "A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia."
06/01/2009 - "In this randomized, double-blind, placebo-controlled study, we evaluated the efficacy and safety of GW406381, an investigational selective cyclooxygenase (COX)-2 inhibitor with both peripheral and central actions, in 209 patients with postherpetic neuralgia (PHN). "
|5.||Migraine Disorders (Migraine)
04/01/2008 - "The objective of the present study was to explore the clinical efficacy and tolerability of GW406381, a cyclooxygenase-2 (COX-2) inhibitor with relatively high CNS penetration, in acute migraine. "
04/01/2008 - "A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine."
04/01/2008 - "Single-dose GW406381 (70 mg) and naproxen sodium (825 mg) were effective and well tolerated in the treatment of acute migraine."
04/01/2008 - "Three hundred and thirty-seven subjects were randomized 1:1:1 to GW406381 (70 mg), naproxen sodium (825 mg), or placebo for the treatment of one migraine headache of moderate or severe intensity in a potential 8-week period. "
|1.||Cyclooxygenase 2 (Cyclooxygenase-2)
|3.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|6.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|1.||Tooth Extraction (Tooth Extractions)